In another study, the authors found that autocrine and paracrine functions of CCL2 are required for prostate cancer growth and invasion, and treatment with a CCR2 antagonist reduced the CCL2-mediated prostate cancer growth and invasion (78). This evidence concerns the gene CCR2 and prostate carcinoma.